Sandoz Strikes $195m Deal On US Price-Fixing

Admits Role In Antitrust Conspiracies As Part Of US Investigation

Sandoz has agreed to pay a $195m criminal penalty, the largest for a US antitrust case, as part of a deferred prosecution agreement with the US Department of Justice to resolve antitrust allegations as part of the country’s ongoing investigation into generic price-fixing.

Gavel
Sandoz has agreed to pay a $195m criminal penalty, which the DoJ said was the largest for a US antitrust case • Source: Shutterstock

Sandoz has agreed to pay a $195m criminal penalty, the largest seen for a US antitrust case, as part of a deferred prosecution agreement with the US Department of Justice to resolve antitrust allegations as part of the country’s ongoing investigation into generic price-fixing.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By 

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By 

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

Glenmark’s UK Dapagliflozin Blocked On Appeal After Teva Readied Launch

 
• By 

Glenmark’s advantage for its UK generic version of AstraZeneca’s Forxiga (dapagliflozin) has quickly been snuffed out, after the originator won on appeal its request for injunctive relief.

Sandoz Admits To Widescale Infringement In Resolving US Rinvoq Patent Tussle

 
• By 

Sandoz has reached an agreement with AbbVie to dismiss without prejudice patent-infringement litigation involving more than 20 patents shielding the originator’s blockbuster JAK inhibitor Rinvoq.

More from Generics Bulletin